Flow Contract Site Laboratory

Executive Summary

Flow Contract Site Laboratory (FCSL) is a specialized contract research organization (CRO) focused exclusively on flow cytometry testing services, supporting drug development from early discovery through clinical trials. The company offers customized assay development, immunophenotyping, receptor occupancy, and functional assays. FCSL is now part of the TD2 family, which enhances its integrated service offerings and expands its client base. As a private, pre-clinical stage company based in San Diego, FCSL operates in the diagnostics segment and has been in business since 2010 without disclosed funding or valuation. Its role as a service provider in the drug development ecosystem positions it to benefit from increasing R&D outsourcing trends.

Upcoming Catalysts (preview)

• Q4 2026Integration with TD2's broader CRO services to offer bundled packages70% success
• Q3 2026New clinical trial contracts from biopharma partners60% success
• Q2 2027Expansion of assay portfolio into emerging modalities (e.g., cell therapy)50% success